Stocks and Investing Stocks and Investing
Thu, March 12, 2020
Wed, March 11, 2020

Alethia Young Reiterated (VRTX) at Buy with Increased Target to $275 on, Mar 11th, 2020


Published on 2024-10-26 23:37:00 - WOPRAI, Alethia Young
  Print publication without navigation


Alethia Young of Cantor Fitzgerald, Reiterated "Vertex Pharmaceuticals Incorporated" (VRTX) at Buy with Increased Target from $262 to $275 on, Mar 11th, 2020.

Alethia has made no other calls on VRTX in the last 4 months.



There are 9 other peers that have a rating on VRTX. Out of the 9 peers that are also analyzing VRTX, 1 agrees with Alethia's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Brian Skorney of "Baird" Downgraded from Buy to Hold and Increased Target to $230 on, Friday, January 31st, 2020


These are the ratings of the 8 analyists that currently disagree with Alethia


  • Brian Abrahams of "RBC Capital" Maintained at Buy with Increased Target to $260 on, Friday, January 31st, 2020
  • Evan Seigerman of "Credit Suisse" Maintained at Buy with Increased Target to $258 on, Friday, January 31st, 2020
  • Kevin Huang of "CFRA" Maintained at Strong Buy with Increased Target to $286 on, Friday, January 31st, 2020
  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $251 on, Friday, January 31st, 2020
  • Paul Matteis of "Stifel" Maintained at Strong Buy with Increased Target to $275 on, Friday, January 31st, 2020
  • Ying Huang of "B of A Securities" Maintained at Strong Buy with Increased Target to $295 on, Friday, January 31st, 2020
  • Hartaj Singh of "Oppenheimer" Maintained at Buy with Increased Target to $265 on, Wednesday, January 8th, 2020
  • Edward Tenthoff of "Piper Sandler" Maintained at Buy with Increased Target to $284 on, Monday, January 6th, 2020
Contributing Sources